Applications
The clinical pharmacology of ivermectin — a macrocyclic lactone derived from the soil bacterium Streptomyces avermitilis — is established in veterinary and human medicine as a highly effective antiparasitic agent. Its mechanism of action involves selective potentiation of glutamate-gated chloride channels in invertebrate neurons, causing irreversible hyperpolarization and paralysis of susceptible parasites.
The Antiparasitic Pharmacology & Clinical Applications of Ivermectin hub provides evidence-based pharmacological analysis. Core attributes include the drug’s high selectivity for invertebrate over vertebrate glutamate-gated channels (explaining its favorable safety profile in mammals), its efficacy against onchocerciasis (river blindness), strongyloidiasis, and ectoparasites, and the WHO Essential Medicine designation for specific indications. The scientific value lies in accurately defining validated clinical use versus unsubstantiated extrapolation.
Pharmacokinetics & Resistance Mechanisms
We examine ivermectin’s high lipophilicity, its extensive distribution into adipose tissue, and its metabolism via CYP3A4 (relevant for drug interactions with P-glycoprotein inhibitors). Our clinical guides focus on evidence-based dosing for approved indications and the emerging public health crisis of anthelmintic resistance in veterinary applications driven by subtherapeutic dosing. Understanding the pharmacology separates evidence-based medicine from misinformation.
FAQ: Ivermectin Pharmacology
Why is ivermectin safe for humans but lethal to parasites? Mammals have a blood-brain barrier that excludes ivermectin from the central nervous system, where the glutamate-gated chloride channels it targets are located. Parasites lack this barrier, so the drug freely accesses and paralyzes their nervous systems at doses harmless to the host.
What are the WHO-approved indications for ivermectin in humans? The WHO recommends ivermectin for onchocerciasis (river blindness), lymphatic filariasis (as part of mass drug administration), strongyloidiasis, and scabies. These are the indications with robust clinical trial evidence supporting efficacy and safety.
Availability: Access & Policy.
